Dana-Farber Cancer Institute: Glioma trials

The registry lists 10 Glioma studies with Dana-Farber Cancer Institute as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 4Phase 2 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Perampanel on Peritumoral Hyperexcitability in HGGCompletedNCT04497142Phase 1/2Results posted
• Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade GliomasCompletedNCT00782626Phase 2Results posted
• GROW (Glioma Specialists Reaching Out With Support) SupportWithdrawnNCT05233215Not applicable
• ASP8374 + Cemiplimab in Recurrent GliomaCompletedNCT04826393Phase 1
• Phase I Study of Marizomib + Panobinostat for Children With DIPGTerminatedNCT04341311Phase 1
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Active, not recruitingNCT03152318Phase 1
• MK-2206 for Recurrent Malignant GliomaWithdrawnNCT01249105Phase 2
• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00165477Phase 2
• Prolonged Daily Temozolomide for Low-Grade GliomaCompletedNCT00165360Phase 2
• Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant GliomaCompletedNCT00047281Phase 2